CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Empagliflozin improves blood pressure in patients with type 2 diabetes (T2DM) and hypertension
DOI 10.1055/s-0034-1374901
Bibliografische Angaben
Nachweis in CareLit
Autor:innenI Tikkanen, K Narko, C Zeller, A Green, A Salsali, UC Broedl, HJ Woerle
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe05/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background, methods: Efficacy, safety and tolerability of empagliflozin (EMPA) were investigated in patients with T2DM and hypertension in a randomized, double-blind Phase III trial. Patients received EMPA 10 mg (n = 276), 25 mg (n = 276) or placebo (PBO; n = 272) qd for 12 weeks. Co-primary endpoints were changes from baseline in HbA1c and mean 24-hour systolic blood pressure (SBP) by ambulatory BP monitoring (ABPM…
Zitieren
Zitierempfehlung
I Tikkanen, K Narko, C Zeller, A Green, A Salsali, UC Broedl, HJ Woerle (2014) Empagliflozin improves blood pressure in patients with type 2 diabetes (T2DM) and hypertension. Diabetologie und Stoffwechsel (05). https://doi.org/10.1055/s-0034-1374901
Mit CareLit weiterarbeiten